Chapin Davis
TRVI icon

Chapin Davis’s Trevi Therapeutics TRVI Stock Holding History

Chapin Davis’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$288K Hold
20,100
– – 0.06% 192
2026
Q2 		$375K Hold
20,100
– – 0.07% 170
2026
Q1 		$240K Hold
20,100
– – 0.05% 227
2025
Q4 		$252K Sell
20,100
-15,000
-43% -$173K 0.06% 207
2025
Q3 		$321K Buy
+35,100
New +$263K 0.08% 188

Other funds holding TRVI

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.25B AUM 28.18% 1-Year Est. Return
PFS Partners
PFS Partners Mine Hill, New Jersey $246M AUM 22.61% 1-Year Est. Return
Harbour Capital Advisors
Harbour Capital Advisors Tysons Corner, Virginia $548M AUM 37.76% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
Albion Financial Group
Albion Financial Group Salt Lake City, Utah $1.77B AUM 14.95% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Hilton Head Capital Partners
Hilton Head Capital Partners Hilton Head Island, South Carolina $185M AUM 26.97% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Chapin Davis's TRVI Position: Q3 2026 in Review

Chapin Davis held its Trevi Therapeutics (TRVI) position steady in Q3 2026 at 20,100 shares worth $288K. The position accounts for 0.06% of the portfolio, ranked #192.

Chapin Davis first reported a position in TRVI in Q3 2025 and has held it in 5 quarters since. The position peaked at $375K in Q2 2026. 21 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

  • Chapin Davis held 20,100 shares of Trevi Therapeutics worth $288K as of Q3 2026.
  • Chapin Davis left its Trevi Therapeutics share count unchanged in Q3 2026.
  • Trevi Therapeutics made up 0.06% of Chapin Davis's portfolio in Q3 2026, its #192 holding.
  • Chapin Davis first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Chapin Davis's Trevi Therapeutics position peaked at $375K in Q2 2026.
  • 21 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on Chapin Davis's 13F filing for Q3 2026, filed 9 Oct 2026.